BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 16, Issue 10
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis
©The Author(s) 2025.
World J Diabetes. Oct 15, 2025; 16(10): 110174
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.110174
Figure 5
Full Size Figure Download Figure
Figure 5 Results of the effects of different types of antidiabetic drugs on hepatocellular cancer, renal cancer, and hematologic cancer. A and B: Hepatocellular cancer; C and D: Renal cancer; E and F: Hematologic cancer. DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT-2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 receptor agonists; CI: Confidence interval.
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.